**Strongyloides stercoralis** hyperinfection in a post-renal transplant patient

Hussain Issa
Mohamad A Aljama
Ahmed H Al-Salem

1Department of Internal Medicine, King Fahad Specialist Hospital, 2Department of Pediatric Surgery, Maternity and Children Hospital, Dammam, Saudi Arabia

**Abstract:** *Strongyloides stercoralis* is an intestinal nematode that is able to infect the host tissue and persist asymptomatic for many years through autoinfection. It causes life-threatening hyperinfection in immunocompromised hosts. This report describes a rare case of strongyloidiasis in a 40-year-old male following renal transplant, which was diagnosed by colonoscopic biopsy. The literature on the subject is also reviewed.

**Keywords:** *Strongyloides stercoralis*, hyperinfection, immunosuppression

**Introduction**

*Strongyloides stercoralis* is a soil-transmitted intestinal nematode that has been estimated to infect at least 60 million people, especially in tropical and subtropical regions. Many infected patients are completely asymptomatic and the infection can remain undetected for years. The uncomplicated intestinal form of the disease usually produces nonspecific abdominal symptoms with or without mild sporadic diarrhea. *Strongyloides* infection, in contrast, has been described in a variety of conditions including those on immunosuppressant therapy, post-transplantation, hematologic malignant disease, human immunodeficiency virus, malnutrition, diabetes mellitus, rheumatoid arthritis, chronic renal failure, hypogammaglobulinemia, and chronic alcohol consumption. In these patients, hyperinfection can occur, which, if not recognized and treated aggressively, can result in mortality rates as high as 87%. In humans, *S. stercoralis* infestation most commonly involves the upper small intestine and the usual clinical presentation is nonspecific and vague and the infestation can mimic several other conditions such as inflammatory bowel disease. Given the increasing numbers of immunocompromised individuals, physicians caring for these patients should be aware of this potential and sometimes fatal complication. This report describes a 40-year-old male who underwent renal transplant and developed colonic hyperinfection with *S. stercoralis*.

**Case report**

In 2008, a 40-year-old male was diagnosed with end-stage renal disease of unknown etiology and was started on regular hemodialysis. During this time he was also found to be hypertensive and was treated with antihypertensive medications. In February 2010, he underwent renal transplant after induction with antithymoglobulin. Four months after the operation, he started to complain of severe nausea, vomiting, and significant loss of weight. At the time of presentation, he was maintained on: tacrolimus 1 mg orally twice daily, mycophenolate mofetil 500 mg orally three times daily, prednisolone 5 mg orally...
once daily, esomeprazole 40 mg orally once daily, bisoprolol 5 mg orally once daily, methyldopa 500 mg orally three times daily, and calcitriol and cotrimoxazole 480 mg orally twice daily. His examination was normal apart from a palpable transplanted kidney in the right iliac fossa. Investigations showed a white blood cell count of $6.19 \times 10^9$/L; neutrophils $5.37 \times 10^9$/L (87.1%); eosinophils $2.5 \times 10^9$/L (0.15%); hemoglobin 10.4 g/dL; hematocrit 33.2%, with a mean cell volume of 80.1 and a mean cell hemoglobin of 26.2. His platelet count was $301 \times 10^9$/L, renal panel showed creatinine of 145 µmol/L, blood urea nitrogen 6.3 mmol/L, sodium 128 mmol/L, and potassium 3.7 mmol/L. He underwent upper gastrointestinal endoscopy, which showed mild gastritis, and the biopsy was negative for *Helicobacter pylori*. As there was no improvement on proton pump inhibitors and prokinetics, colonoscopy was performed. This revealed aphthoid-like ulcers at the rectum and rectosigmoid areas. The ascending colon showed mucosal segments with granularity, pin-point ulceration with fibrin deposits (see Figure 1), and bleeding on touch. The findings were suggestive of inflammatory bowel disease. However, the biopsy revealed focal nonspecific inflammation, with larva-like parasites spotted on rectal biopsy (see Figure 2). Fecal examination confirmed the presence of a large number of *S. stercoralis*. He was started on a 10-day course of albendazole 400 mg orally twice daily. His symptoms subsided and he gradually started gaining weight. Fecal examinations 2 and 4 weeks after the initiation of therapy were normal.

**Discussion**

*S. stercoralis* is an intestinal nematode of humans. Although most infected individuals are asymptomatic, *S. stercoralis* is capable of causing a fulminant illness that is often fatal if not recognized and treated. This is seen in certain conditions associated with a decrease in host immunity, including immunosuppressive therapy (particularly the use of glucocorticoids), hematological malignancies, bone marrow and renal transplants, human T-cell lymphotropic virus type 1 infection, human immunodeficiency virus infection, hypogammaglobulinemia, and malnutrition. Although various immunocompromising conditions have been associated with hyperinfection, steroids and human T-cell lymphotropic virus type 1 infection are the most consistent. In these conditions *S. stercoralis* causes hyperinfection. The patient discussed had a *S. stercoralis* hyperinfection following renal transplant. Of interest is that the majority of cases of hyperinfection with *S. stercoralis* that have occurred following organ transplant were seen in patients following renal transplant and most of these cases seem to have been precipitated by increased glucocorticoid doses in response to rejection. The authors’ patient did not show signs of rejection, but he was on glucocorticoid therapy and this probably contributed to the development of superinfection. Given the increasing numbers of immunocompromised patients throughout the world, this calls for a closer evaluation and observation of all conditions under which *S. stercoralis* infection becomes dangerous. This is of paramount importance to physicians caring for these patients, as early identification and treatment of those at risk is likely to decrease the morbidity and mortality associated with *S. stercoralis* superinfection.

*S. stercoralis* commonly causes gastrointestinal symptoms that are nonspecific and easily attributed to other diseases. This was the case in the patient discussed, who was complaining of nausea and vomiting only; the striking and alarming feature was the sudden and significant weight loss. This called for further investigation including colonoscopy, which showed features suggestive of inflammatory bowel disease. The diagnosis of *S. stercoralis* infection was made on colonic biopsy and subsequently on fecal examination. The definitive diagnosis of *S. stercoralis* infection depends on the demonstration of larvae in the feces or duodenal fluid. In uncomplicated cases, the intestinal worm load is low and larval output is minimal. A single fecal examination thus fails to detect larvae in up to 70% of cases. Repeated fecal examinations increase the sensitivity of detection of *S. stercoralis* infection.

*Figure 1* Colonoscopic picture showing aphthoid-like ulcers, granularity, and pin-point ulceration with fibrin deposits.
In immunocompromised patients, the autoinfective cycle of *S. stercoralis* can become amplified into a potentially fatal hyperinfection syndrome, characterized by increased numbers of infective filariform larvae in the feces.

Strongyloidiasis is a curable disease and early diagnosis and appropriate therapy with anthelmintics can reduce morbidity and mortality. Ivermectin, when compared with albendazole and thiabendazole, shows similar or better rates of larval clearance from feces with similar side effects but is much better tolerated and has become the treatment of choice. An important point which must be considered is the fact that hyperinfections are often complicated by infections caused by gut flora that gain access to extra-intestinal sites, presumably through gut ulcers induced by the filariform larvae. Gut flora can include *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Pseudomonas* spp, *Enterococcus faecalis*, coagulase-negative staphylococci, *Streptococcus bovis*, and *Streptococcus pneumoniae*. Patients on immunosuppressive therapy may also develop systemic candidiasis in addition to enteric Gram-negative infections.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


